• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Cost of cancer diagnosis using next-generation ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1038/s41431-017-0081-3
PMID :
29367707
Permalink :
http://hdl.handle.net/20.500.12210/4585
Title :
Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study
Author(s) :
Marino, Patricia [Auteur]
Touzani, Rajae [Auteur]
Perrier, Lionel [Auteur]
Rouleau, Etienne [Auteur]
Kossi Dede, Sika [Auteur]
Zou, Zhaomin [Auteur]
Charrier, Nathanael [Auteur]
Goardon, Nicolas [Auteur]
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Durand-Zaleski, Isabelle [Auteur]
Borget, Isabelle [Auteur]
Baffert, Sandrine [Auteur]
Baffert, Sandrine [Auteur]
Barillot, Emmanuel [Auteur]
Bezieau, Stephane [Auteur]
Borget, Isabelle [Auteur]
Coppin, Lucie [Auteur]

Descapentries, Clothilde [Auteur]
Durand-Zaleski, Isabelle [Auteur]
Forget, Sebastien [Auteur]
Frebourd, Thierry [Auteur]
Guardiola, Philippe [Auteur]
Goardon, Nicolas [Auteur]
Houdayer, Claude [Auteur]
Hupe, Philippe [Auteur]
Lacroix, Ludovic [Auteur]
Leclerc, Julie [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Lespagnol, Alexandra [Auteur]
Longuemare, Stephanie [Auteur]
Marino, Patricia [Auteur]
Mosser, Jean [Auteur]
Odou, Marie Francoise [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Perrier, Lionel [Auteur]
Preudhomme, Claude [Auteur]
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer (JPArc) - U1172
Revillion, Francoise [Auteur]
Rouleau, Etienne [Auteur]
Sevenet, Nicolas [Auteur]
Soubeyran, Isabelle [Auteur]
Vaur, Dominique [Auteur]
Journal title :
European journal of human genetics
Abbreviated title :
Eur. J. Hum. Genet.
Volume number :
26
Pages :
314-323
Publication date :
2018-03-01
ISSN :
1018-4813
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
It is currently unclear if next-generation sequencing (NGS) technologies can be implemented in the diagnosis setting at an affordable cost. The aim of this study was to measure the total cost of performing NGS in clinical ...
Show more >
It is currently unclear if next-generation sequencing (NGS) technologies can be implemented in the diagnosis setting at an affordable cost. The aim of this study was to measure the total cost of performing NGS in clinical practice in France, in both germline and somatic cancer genetics.The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. In addition, we used a top-down methodology for specific post-sequencing steps including bioinformatics, technical validation, and biological validation. Additional non-specific costs were also included. Costs were detailed per step of the process (from the pre-analytical phase to delivery of results), and per cost driver (consumables, staff, equipment, maintenance, overheads). Sensitivity analyses were performed.The mean total cost of NGS for targeted gene panels was estimated to 607euro (+/-207) in somatic genetics and 550euro (+/-140) in germline oncogenetic analysis. Consumables were the highest cost driver of the sequencing process. The sensitivity analysis showed that a 25% reduction of consumables resulted in a 15% decrease in total NGS cost in somatic genetics, and 13% in germline analysis. Additional costs accounted for 30-32% of the total NGS costs.Beyond cost assessment considerations, the diffusion of NGS technologies will raise questions about their efficiency when compared to more targeted approaches, and their added value in a context of routine diagnosis.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • Lille Neurosciences & Cognition (LilNCog) - U 1172
Research team(s) :
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
Submission date :
2019-03-01T14:17:25Z
Université de Lille

Mentions légales
Université de Lille © 2017